respiratory
Lung cancer

ALK inhibitor suitable for first line therapy in NSCLC

The ALK inhibitor lorlatinib could be used in first line treatment of ALK-rearranged non-small-cell lung cancer (NSCLC) because of its high efficacy against brain metastases, an Australian-led phase 3 trial has shown. An interim analysis of the CROWN trial, presented at ESMO Virtual Congress 2020 by Professor Ben Solomon, medical oncologist at the Peter MacCallum ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic